<p>拜耳公司在上半年制药部门表现强于预期后更新了其财务展望。该公司为 Roundup（草甘膦）诉讼建立了约 12 亿欧元的额外准备金。该数字包含在约 17 亿欧元的总额中。</p>
<p>拜耳在 2025 年第二季度实现集团销售额约为 107 亿欧元。季度核心每股收益增加至 1.23 欧元，主要受益于财务结果的同比改善和税费的降低。</p>
<p>该公司现在预计 2025 年全年集团销售额将在 460 亿欧元至 480 亿欧元之间，较之前预测的 450 亿欧元至 470 亿欧元有所上调。特殊项目前的 EBITDA 预计将在 97 亿欧元至 102 亿欧元之间，修订自之前的 95 亿欧元至 100 亿欧元。</p>
<p>拜耳还将核心每股收益的预测上调至 4.80 欧元至 5.30 欧元，而之前的范围为 4.50 欧元至 5.00 欧元。同时，自由现金流的预测保持在 15 亿欧元至 25 亿欧元之间，净金融债务仍预计在 310 亿欧元至 320 亿欧元之间。</p>
<p>拜耳表示，它正在持续评估当前地缘政治发展的影响，特别是与美国政府的关税相关的影响。目前预计的财务影响已在更新的全年指导中考虑。</p>
<p>拜耳预计货币影响将使集团销售额减少约 20 亿欧元，特殊项目前的 EBITDA 减少约 5 亿欧元，核心每股收益减少约 0.35 欧元。关于净金融债务，该公司预计货币将带来 12 亿欧元的积极影响。</p>
<p>拜耳表示，将于 2025 年 8 月 6 日公布第二季度的详细业绩。</p>
<p>如需评论和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

拜耳

拜耳(ADR)

<p>拜耳股份公司已将其全年销售预期上调至 460 亿至 480 亿欧元，较之前的 450 亿至 470 亿欧元有所增加，这得益于其制药部门的强劲表现。公司为草甘膦诉讼额外拨款 12 亿欧元，使总额达到 17 亿欧元。核心每股收益现预计为 4.80 至 5.30 欧元，较之前的预测有所上升。拜耳预计货币因素将使销售额减少约 20 亿欧元，EBITDA 减少约 5 亿欧元。详细的第二季度业绩将于 2025 年 8 月 6 日公布</p>

<p>Bayer AG updated its financial outlook following stronger-than-expected performance in its Pharmaceuticals division during the first half of the year. The company has established additional provisions of around 1.2 billion euros for the Roundup (glyphosate) litigation. This figure is included in the around 1.7 billion euros total.</p>
<div class="lb-trans"><p>拜耳公司在上半年制药部门表现强于预期后更新了其财务展望。该公司为 Roundup（草甘膦）诉讼建立了约 12 亿欧元的额外准备金。该数字包含在约 17 亿欧元的总额中。</p>
</div><p>Bayer generated Group sales of approximately 10.7 billion euros in the second quarter of 2025. Quarterly core earnings per share increased to 1.23 euros, mainly driven by a year-on-year improvement in the financial result and lower tax expense.</p>
<div class="lb-trans"><p>拜耳在 2025 年第二季度实现集团销售额约为 107 亿欧元。季度核心每股收益增加至 1.23 欧元，主要受益于财务结果的同比改善和税费的降低。</p>
</div><p>The company now projects full-year 2025 Group sales between 46 billion euros and 48 billion euros, up from its earlier forecast of 45 billion euros to 47 billion euros. EBITDA before special items is expected to range from 9.7 billion euros to 10.2 billion euros, revised from the previous 9.5 billion euros to 10.0 billion euros.</p>
<div class="lb-trans"><p>该公司现在预计 2025 年全年集团销售额将在 460 亿欧元至 480 亿欧元之间，较之前预测的 450 亿欧元至 470 亿欧元有所上调。特殊项目前的 EBITDA 预计将在 97 亿欧元至 102 亿欧元之间，修订自之前的 95 亿欧元至 100 亿欧元。</p>
</div><p>Bayer also raised its forecast for core earnings per share to 4.80 euros to 5.30 euros, compared to its earlier range of 4.50 euros to 5.00 euros. Meanwhile, the projections for free cash flow remain steady at 1.5 billion euros to 2.5 billion euros, and net financial debt is still expected to fall within 31.0 billion euros to 32.0 billion euros.</p>
<div class="lb-trans"><p>拜耳还将核心每股收益的预测上调至 4.80 欧元至 5.30 欧元，而之前的范围为 4.50 欧元至 5.00 欧元。同时，自由现金流的预测保持在 15 亿欧元至 25 亿欧元之间，净金融债务仍预计在 310 亿欧元至 320 亿欧元之间。</p>
</div><p>Bayer said it is continuously evaluating the impacts of the current geopolitical developments, especially in relation to tariffs from the US government. The currently projected financial effects are accounted for in the updated full-year guidance.</p>
<div class="lb-trans"><p>拜耳表示，它正在持续评估当前地缘政治发展的影响，特别是与美国政府的关税相关的影响。目前预计的财务影响已在更新的全年指导中考虑。</p>
</div><p>Bayer expects currency effects to diminish Group sales by around 2 billion euros, EBITDA before special items by approximately 500 million euros, and core earnings per share by about 0.35 euros. Regarding net financial debt, the company expects a positive impact of 1.2 billion euros from currency.</p>
<div class="lb-trans"><p>拜耳预计货币影响将使集团销售额减少约 20 亿欧元，特殊项目前的 EBITDA 减少约 5 亿欧元，核心每股收益减少约 0.35 欧元。关于净金融债务，该公司预计货币将带来 12 亿欧元的积极影响。</p>
</div><p>Bayer said it will publish detailed results for the second quarter on August 6, 2025.</p>
<div class="lb-trans"><p>拜耳表示，将于 2025 年 8 月 6 日公布第二季度的详细业绩。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如需评论和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

拜耳公司上调了全年集团销售预期，并为草甘膦诉讼额外拨款 12 亿欧元